SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden [see comments] [published erratum appears in JAMA 1997;278:206]. JAMA 1997;277: 46771.
  • 2
    Franklin CI, Parker CA, Morton KM. Late effects of radiation therapy for prostate carcinoma: the patient's perspective of bladder, bowel and sexual morbidity. Australas Radiol 1998; 42: 5865.
  • 3
    Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 26772.
  • 4
    Pilepich MV, Asbell SO, Krall JM, Baerwald WH, Sause WT, Rubin P. Correlation of radiotherapeutic parameters and treatment related morbidity—analysis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys 1987; 13: 100712.
  • 5
    Pilepich MV, Krall JM, Sause WT, Johnson RJ, Russ HH, Hanks GE, et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate—analysis of rtog study 75-06. Int J Radiat Oncol Biol Phys 1987; 13: 3517.
  • 6
    Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequele following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21: 9359.
  • 7
    Mameghan H, Fisher R, Mameghan J, Watt WH, Tynan A. Bowel complications after radiotherapy for carcinoma of the prostate: the volume effect. Int J Radiat Oncol Biol Phys 1990; 18: 31520.
  • 8
    Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 74: 252032.
  • 9
    Fransson P, Widmark A. Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age-matched control group. Cancer 1996;78: 106678.
  • 10
    Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy- induced side effects. Support Care Cancer. 2001;9: 18798.
  • 11
    Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998; 16: 27583.
  • 12
    Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer [see comments]. JAMA 1995; 273: 12935.
  • 13
    Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996;5: 21222.
  • 14
    Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 73543.
  • 15
    Joly F, Brune D, Couette JE, Lesaunier F, Heron JF, Peny J, et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998; 9: 7517.
  • 16
    Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer 1997; 79: 197786.
  • 17
    Borghede G, Karlsson J, Sullivan M. Quality of life in patients with prostatic cancer: results from a Swedish population study. J Urol 1997; 158: 147785.
  • 18
    Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 22603.
  • 19
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 36576.
  • 20
    Bjordal K, Kaasa S. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 1992; 31: 31121.
  • 21
    Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995; 13: 124954.
  • 22
    Watanabe K, Hoshi N, Hiraki H, Yamaki T, Tsu-Ura Y, Suzuki T. Neoplastic endocrine cells in prostatic carcinoma: a case report with immunocytochemical and electron microscopic findings. Fukushima J Med Sci 1995; 41: 5160.
  • 23
    Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 35364.
  • 24
    King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996; 5: 55567.
  • 25
    Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+3). J Clin Oncol 1998; 16: 118896.
  • 26
    Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998; 51: 9917.
  • 27
    Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology 1996; 47: 38794.
  • 28
    Widmark A, Fransson P, Franzen L, Littbrand B, Henriksson R. Daily-diary evaluated side-effects of conformal versus conventional prostatic cancer radiotherapy technique. Acta Oncol 1997; 36: 499507.
  • 29
    Breetvelt IS, Van Dam FS. Underreporting by cancer patients: the case of response-shift. Soc Sci Med 1991; 32: 9817.
  • 30
    Cassileth BR, Lusk EJ, Strouse TB, Miller DS, Brown LL, Cross PA, et al. Psychosocial status in chronic illness. A comparative analysis of six diagnostic groups. N Engl J Med 1984;311: 50611.
  • 31
    Cassileth BR, Lusk EJ, Tenaglia AN. A psychological comparison of patients with malignant melanoma and other dermatologic disorders. J Am Acad Dermatol 1982; 7: 7426.
  • 32
    Johansson J, Adami H, Andersson S, Bergström R, Krusemo U, Kraaz W. Natural history of localized prostatic cancer. Lancet 1989; 15: 799803.
  • 33
    Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L. High 10-year survival rate in patients with early, untreated prostatic cancer [see comments]. JAMA 1992; 267: 21916.
  • 34
    Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer [see comments]. Cancer 1993; 72: 31022.
  • 35
    Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer [see comments]. J Urol 1994; 152: 18179.
  • 36
    Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer [see comments]. Lancet 1997; 349: 90610.